Lipid Metabolism Regulating Enzyme PPAP2C Identified as Key Factor Driving Aggressiveness and Poor Prognosis in Refractory Breast Cancer
Background
Breast cancer is a leading cause of cancer-related mortality among women worldwide and exhibits high heterogeneity according to molecular subtypes. Advances in precision therapy tailored to the presence or absence of hormone receptor and human epidermal growth factor receptor 2 (HER2) expression. However, triple-negative breast cancer (TNBC) with all three receptors deficient still has limited targeted therapy options. Many patients experience early recurrence after chemotherapy and face refractory states. There is an urgent need to identify novel targets to improve survival rates for this subtype.
Recently, the oncology community has been focusing on the abnormal lipid metabolism reprogramming of cancer cells. Malignant tumors disrupt phospholipid metabolism to activate survival signals for rapid proliferation. This is the background for the growing interest in the role of the Phospholipid Phosphatase (PLPP) family, which mediates metabolic regulation. In particular, the function of Phosphatidic Acid Phosphatase Type 2C (PPAP2C) remained unclear. This was a time when there was an urgent need to identify metabolic vulnerabilities.
Key Findings
The researchers performed an integrated analysis of The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) database, and the Cancer Cell Line Encyclopedia (CCLE). A comparison across 33 cancer types revealed that PPAP2C expression increased in 16 types and decreased in only 3. This represents the most pronounced overexpression pattern among all cancer types. Expression levels surged in breast cancer tissues compared to normal tissues, and the intensity of expression increased proportionally as the disease stage progressed.
Molecular subtype analysis showed concentrated expression increases in HER2-positive and TNBC, which have poor prognoses. The researchers verified survival correlations using TCGA, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and Gene Expression Omnibus (GEO) cohorts. The high-PPAP2C group showed unfavorable results in both overall survival and recurrence-free survival compared to the low-expression group. Its value as an independent prognostic factor was confirmed via multivariate Cox analysis. Using Immunohistochemistry (IHC) on Tissue Microarray (TMA) specimens, they confirmed the same trend of worsening prognosis at the protein level.
To reveal protein function, cellular-level functional evaluations were conducted. Using CRISPR-Cas9 technology on highly aggressive TNBC cell lines, researchers established knockout and overexpression models. Cancer cells with blocked PPAP2C expression showed slowed proliferation rates and reduced colony formation. Cell motility and invasive capacity significantly decreased compared to the control group. Conversely, under conditions of gene overexpression, cancer cell motility and invasiveness increased dramatically. This provides experimental evidence that this enzyme acts as a functional driver regulating the malignant phenotype of breast cancer.
Significance and Outlook
This study suggests that a specific enzyme in lipid metabolism functions as a key molecular switch determining breast cancer malignancy. To date, breast cancer targeted therapy has been largely focused on protein kinase inhibitors or hormone blockers. The discovery of a new target that directly regulates lipid metabolites expands the therapeutic landscape for refractory breast cancer. The alignment between protein-level verification using patient specimens and big-data cohort analysis supports the potential for future clinical application as a biomarker.
The immediate challenges that follow-up research must address are also clear. Since the aggressive phenotype was verified in cell line models, additional verification in animal experiments and organoid models is required. Analysis must also follow to identify which downstream metabolite pathways trigger tumor growth during the dephosphorylation of phosphatidic acid by PPAP2C. The fact that a dedicated inhibitor has not yet been developed is also identified as a barrier to overcome. If the synthesis of inhibitors that precisely target the enzyme's active site accelerates, it is expected to emerge as a promising pipeline to fill the therapeutic gap.
BACKGROUND: This study aims to systematically elucidate the clinical significance and biological function of the phospholipid phosphatase (PLPP) family member (PPAP2C) phosphatidic acid phosphatase type 2C in breast cancer, and to evaluate its potential as a prognostic biomarker and therapeutic target. METHODS: Gene expression data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Line Encyclopedia (CCLE) databases were integrated to characterize the expression profile of PLPP family members, focusing on PPAP2C in breast cancer. The prognostic value of PPAP2C, initially identified at the mRNA level (TCGA, (METABRIC) Molecular Taxonomy of Breast Cancer International Consortium, Gene Expression Omnibus (GEO)), was confirmed at the protein level by immunohistochemistry (IHC) on tissue microarrays (TMA). The oncogenic functions of PPAP2C were investigated in triple-negative breast cancer (TNBC) cells through CRISPR-Cas9-mediated knockout and ectopic overexpression, with assessment of key phenotypes including proliferation, colony formation, migration, and invasion. RESULTS: PPAP2C exhibits the most significant overexpression pattern across 33 cancer types (upregulated in 16 cancers, downregulated in only 3). Compared with normal tissues, PPAP2C showed specific overexpression in breast cancer tissues and was significantly associated with advanced clinical stages and aggressive subtypes (HER2-positive). CONCLUSION: This study identifies PPAP2C as a key oncogenic driver and a robust independent prognostic biomarker in breast cancer. The findings provide compelling evidence that PPAP2C represents a promising therapeutic target, offering a new strategic avenue for precision therapy, particularly for aggressive breast cancer subtypes.
This research can generate direct industrial impact along two key axes: the early screening of patients with aggressive breast cancer and the development of customized therapeutics. This includes the potential commercialization of Companion Diagnostic (CDx) kits that measure PPAP2C protein expression levels via IHC in pre-surgical biopsy or resected specimens. By using it as an auxiliary prognostic tool for patient groups in whom high-risk identification via existing receptor diagnostics is difficult, it becomes possible to establish protocols for providing preemptive treatment to patients expected to experience aggressive metastasis.
In terms of the drug development pipeline, this directly leads to targets for new drug discovery using small molecule compounds or Proteolysis-Targeting Chimera (PROTAC) technology. Refining clinical strategies for patients with metastatic triple-negative breast cancer who have no adequate standard treatment alternatives. Representative approaches include administering PPAP2C inhibitors alone or in combination with immunotherapy to block lipid metabolism signals. The mechanism of inhibiting cancer cell metastasis and proliferation is expected to offer a viable therapeutic alternative for refractory patients who have developed resistance to conventional chemotherapy.